Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2023.0303
Abstract: Importance Anthracycline-containing regimens are highly effective for diffuse large B-cell lymphoma (DLBCL); however, patients with preexisting heart failure (HF) may be less likely to receive anthracyclines and may be at higher risk of lymphoma mortality.… read more here.
Keywords: lymphoma; diagnosis; large cell; mortality ... See more keywords
Risk of Anaplastic Large Cell Lymphoma Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Ductal Carcinoma in Situ
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.43396
Abstract: This cohort study examines the risk of anaplastic large cell lymphoma (ALCL) following postmastectomy implant reconstruction among US women with breast cancer and ductal carcinoma in situ (DCIS). read more here.
Keywords: risk anaplastic; cell lymphoma; postmastectomy implant; large cell ... See more keywords
Anaplastic Large Cell Lymphoma of the Breast by Race and Ethnicity
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2025.28013
Abstract: This cohort study uses data from the Surveillance, Epidemiology, and End Results program to examine the incidence of anaplastic large cell lymphoma of the breast according to the race and ethnicity of US women with… read more here.
Keywords: cell lymphoma; lymphoma breast; large cell; race ethnicity ... See more keywords
MicroRNAs implicated in canine diffuse large B‐cell lymphoma prognosis
Sign Up to like & getrecommendations! Published in 2024 at "FEBS Open Bio"
DOI: 10.1002/2211-5463.13887
Abstract: Diffuse large B‐cell lymphoma (DLBCL) is the most prevalent subtype of non‐Hodgkin lymphoma (NHL) in domestic dogs, with many similarities to its human counterpart. The progression of the disease is rapid, and treatment must be… read more here.
Keywords: cell lymphoma; progression; diffuse large; large cell ... See more keywords
Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24751
Abstract: Global hypomethylation has been linked to disease progression in several cancers, but has not been reported for Diffuse Large B Cell Lymphoma (DLBCL). This study aimed to assess global methylation in DLBCL and describe its… read more here.
Keywords: methylation; global hypomethylation; cfdna; large cell ... See more keywords
A new prognostic model identifies patients aged 80 years and older with diffuse large B‐cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25107
Abstract: The means of optimally managing very elderly patients with diffuse large B‐cell lymphoma (DLBCL) has not been established. We retrospectively analyzed 252 patients aged 80‐100 years, diagnosed with DLBCL or grade 3B follicular lymphoma, treated… read more here.
Keywords: lymphoma; treatment; prognostic model; large cell ... See more keywords
Hiding in (Not So) Plain Sight: Spontaneous Tumor Lysis Syndrome due to Intravascular Large B Cell Lymphoma.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of hematology"
DOI: 10.1002/ajh.26383
Abstract: Tumor lysis syndrome (TLS) is an oncologic emergency characterized by metabolic derangements (e.g., hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia) and clinical complications (e.g., renal failure, cardiac arrhythmia, new-onset seizure). It most often occurs in the setting… read more here.
Keywords: lysis syndrome; cell lymphoma; intravascular large; tumor lysis ... See more keywords
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26579
Abstract: Epstein Barr virus‐positive (EBV+) diffuse large B‐cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the WHO classification of lymphoid neoplasms since 2016. EBV+ DLBCL, NOS, is an aggressive B‐cell lymphoma associated… read more here.
Keywords: cell; cell lymphoma; large cell; diffuse large ... See more keywords
Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26835
Abstract: Advances in molecular profiling of newly diagnosed diffuse large B‐cell lymphoma (DLBCL) have recently refine genetic subgroups. Genetic subgroups remain undetermined at the time of relapse or refractory (RR) disease. This study aims to decipher… read more here.
Keywords: refractory; three genetic; large cell; diffuse large ... See more keywords
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27430
Abstract: Epstein Barr virus‐positive (EBV+) diffuse large B‐cell lymphoma (DLBCL), not otherwise specified (NOS) is an aggressive B‐cell lymphoma associated with EBV infection included in the WHO classification of lymphoid neoplasms since 2016. Although historically associated… read more here.
Keywords: cell lymphoma; cell; diffuse large; large cell ... See more keywords
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27548
Abstract: Chimeric antigen receptor (CAR) T‐cell therapy has revolutionized treatment of aggressive large B‐cell lymphoma (aLBCL). Patients with transformed indolent non‐Hodgkin lymphoma (tiNHL) were included in key CAR trials, but outcomes of CAR for this distinct,… read more here.
Keywords: car; large cell; lymphoma; aggressive large ... See more keywords